Table 1.
Soy bioactive peptides and their properties.
Soy Protein Source | Bioactive Peptide | Properties | Tested Model | Reference |
---|---|---|---|---|
βCG | YVVNPDNDEN | Hypocholesterolemic | HepG2 human liver cells | [36,37] |
YVVNPDNNEN | ||||
LAIPVNKP | ACE inhibition | In vitro ACE inhibitory activity assay | [12,38] | |
LPHF | ||||
βCG (α’-subunit) |
Soymetide-13: MITLAIPVNKPGR | Immunostimulating | Male ICR mice and fMLP receptor binding assay; Phagocytosis assay; Anti-alopecia in neonatal rat model |
[12,34,39] |
Soymetide-9: MITLAIPVN | [34,39,40,41] | |||
Soymetide-4: MITL | ||||
KNPQLR; EITPEKNPQLR; RKQEEDEDEEQQRE | FAS inhibitor | FAS inhibition studies; 3T3-L1mouse adipocyte | [16,42] | |
βCG (β-subunit) |
Soymorphin-5: YPFVV | Anti-diabetic Triglyceride-lowering Immunostimulating Suppress feeding and intestinal transit |
Guinea pig ileum assay opioid activity; Diabetic KKAy mice |
[39,43,44,45] |
Soymorphin-6: YPFVVN | Elevated Plus-Maze Test in Male ddY Mice | |||
Soymorphin-7: YPFVVNA | Male BALB/c and ddY mice | |||
VRIRLLQRFNKRS | Appetite suppressant | Male BALB/c and ddY mice; Male Sprague-Dawley rat; Mouse intestinal STC-1 cells |
[9,39,46,47,48] | |
Glycinin | IAVPGEVA | Hypocholesterolemic Anti-diabetic |
HMGR activity assay; HepG2 human liver cells; DPP-IV activity assay |
[9,36,49,50] |
IAVPTGVA | [36,50,51,52] | |||
LPYP | [36,37,39,49,53] | |||
VLIVP | ACE inhibition | ACE inhibitory assay | [12] | |
SPYP | ||||
WL | ||||
SFGVAE | Hypocholesterolemic | HMGR activity | [49] | |
HCQRPR | Phagocytosis stimulatory peptide | Macrophages; Human polymorphonuclear leukocytes; C3H/He mouse |
[16,39,54] | |
QRPR | ||||
Glycinin (A4 and A5) | LPYPR | Hypocholesterolemic | Mice at dose of 50 mg/kg for 2 days; HMGR activity assay; |
[9,16,34,39,53] |
NWGPLV | ACE inhibition | Spontaneously Hypertensive model rats | [9,12,55] | |
Lunasin | SKWQHQQDSCRKQKQ GVNLTPCEKHIMEKIQ GRGDDDDDDDDD |
Antioxidative Anti-inflammatory Anti-cancer Hypocholesterolemic |
Suppression of skin papilloma development in SENCAR mice by acting as an antimitotic agent; Synergistically works with cytokines (IL-12 or IL-2) to improve the tumoricidal activity of natural killer cells in in vitro and in vivo tumor models; TEN-mediated apoptosis of MCF-7 breast cancer cells; Inhibits production of HMGR and increases LDLR expression; Antioxidant in Caco-2 cells; Inhibit ROS generation in HepG2 cells; Inhibit proinflammatory cascades in THP-1 macrophages |
[11,12,16,29,56] |
Bowman-Birk Inhibitor | Anti-cancer Proteinase inhibition Chemoprevention |
50% reduction in the frequency of chromosomal abnormalities and sister chromatid exchange in blood syndrome patients; Shrink precancerous lesions in the mouth that lead to oral cancer called leukoplakia in humans in Phase I and II clinical trials; Reduction in the level of serum PSA in males with benign prostatic hyperplasia; Blocks the generation of ROS in prostate cancer cells (BRF-55T, 267B1/Ki-ras, LNCaP, and PC-3 cells); protected Balb c/3T3 cells (clones A 31) exposed to UVC irradiation and reduced transformation; |
[57,58,59,60,61,62,63,64,65] | |
Vglycin | Anti-diabetic | Normalize fasting glucose and restore pancreatic function in Type 2 diabetic Wistar rats | [66] | |
Glycinin, βCG-α, βCG-α’, βCG-β, Trypsin Inhibitor & Lipoxygenase | KA | Triglyceride-lowering | HepG2 cells; Male Otsuka Long-Evans Tokushima fatty rats; Male Wistar rats |
[67,68] |
Glycinin, Trypsin Inhibitor & Lipoxygenase | VK | |||
Glycinin, βCG-α, βCG-α’, βCG-β & Lipoxygenase | SY | |||
Defatted soy protein | X-MLPSYSPY | Anti-cancer | Arrest P388D1 mouse monocyte macrophages at G2/M phase to block cell cycle progression | [16,34,69] |
Soy protein | YVVFK; IPPGVPYWT; PNNKPFQ; NWGPLV; TPRVF |
Hypotensive | Spontaneously hypertensive rats | |
Anti-inflammatory | Postmenopausal women; ApoE knockout mice | [70,71,72,73,74] | ||
WGAPSL; VAWWMY; FVVNATSN | Hypocholesterolemic | Rats; HepG2 cells | [12,16,39] | |
Soybean | PGTAVFK | Hypotensive | IC50 = 26.5 µM | [16,34] |
IVF; LLF; LNF; LSW; LEF | ACE inhibition | ACE inhibitory activity assay and UPLC-MS/MS | [75] | |
Flavouzyme®-treated soy protein isolate | ILL; LLL; VHVV | Lipolysis | 3T3-L1 mouse adipocytes | [76] |
Chymotrypsin Korean fermented soybean paste | HHL | Hypotensive | Spontaneously hypertensive rats | [77] |
Genetically modified soybean protein | LLPHH; RPLKPW | Antioxidative; Antihypertensive | [34] | |
Black soybean protein | IQN | Adipogenesis inhibition | 3T3-L1 mouse adipocytes | [16,78] |
Soymilk | RQRK; VIK | Anti-inflammatory | RAW 264.7 mouse macrophages | [79] |
Protease (PROTIN SD-NY10) treated soy milk | FFYY; WHP; FVP; LHPGDAQR; IAV; VNP; LEPP; WNPR | ACE inhibition | ACE inhibitory activity assay | [39,80] |
Fermented soybean, Bacillus natto or subtilis | VAHINVGK | ACE inhibitory activity assay and simulated gastrointestinal digestion | [81] | |
YVWK | ||||
Fermented soybean seasoning | SY GY |
Spontaneously hypertensive rats | [82,83] |